SCHEMBL14056526

SCHEMBL14056526

C=CC(=O)NC1CC2CN(S(=O)(=O)c3ccc(NC(=O)c4cc5c(s4)CCCC5)cc3)CC2C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.49
▸ MAPT P10636 6/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ NPC1 O15118 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ NFKB1 P19838 1/20 0.49
▸ NFKB2 Q00653 1/20 0.49
▸ RELA Q04206 1/20 0.49
▸ TGM2 P21980 3/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ GPR55 Q9Y2T6 6/20 0.47
▸ CNR1 P21554 4/20 0.47
▸ LMNA P02545 4/20 0.46
▸ PRNP P04156 1/20 0.45
▸ HPGD P15428 2/20 0.44
▸ TSHR P16473 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ HTT P42858 2/20 0.44
▸ GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14056638 0.98 ALDH1A1 (0.49) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL14058338 0.95 ALDH1A1 (0.53) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL14057593 0.93 ALDH1A1 (0.52) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL14058107 0.90 ALDH1A1 (0.51) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL14056065 0.89 TGM2 (0.50) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL14055849 0.89 TGM2 (0.53) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL14057202 0.88 MAPT (0.46) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL14056264 0.88 TGM2 (0.49) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL14057469 0.88 ALDH1A1 (0.51) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL14058208 0.87 ALDH1A1 (0.51) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889716-B2 Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof CHDI FOUNDATION, INC. (US) 2014-11-18 — — US disclosed
US-20120302539-A1 TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. 2012-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302539-A1 TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF HTT, TGM2, GRN ALDH1A1 3161/4885MAPT 31/4885SMN1; SMN2 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback